The company references weight-loss outcomes associated with semaglutide, including a figure of "15-20% average body weight loss." Those figures are tied to broader clinical literature about FDA-approved branded semaglutide products studied in formal clinical trials and should not be interpreted as established outcomes for the compounded formulations dispensed through this telehealth platform
Mol Pharmacol (2005) 68(3):84754
The cheeks, forehead, and chin typically tolerate concentrations well
Focusing on improving side effects associated with glucagon-like peptide-1 agonist (GLP-1) therapies, there is an increased requirement for nutrition support products, hydration solutions, and educational materials
[1] Weekly GLP-1 injections: Wegovy
By promoting relaxation and reducing cortisol spikes before bedtime, use of this peptide may assist in achieving deeper, more restorative sleep